Ardelyx Inc (NASDAQ:ARDX) major shareholder Ventures Vii Lp Cmea bought 316,826 shares of Ardelyx stock on the open market in a transaction that occurred on Tuesday, June 24th. The shares were purchased at an average price of $14.00 per share, for a total transaction of $4,435,564.00. Ardelyx Inc (NASDAQ:ARDX) stock performance was 5.14% in last session and finished the day at $20.44. Traded volume was 19,547.00million shares in the last session and the average volume of the stock remained 200.45K shares. Ardelyx Inc (NASDAQ:ARDX) insider ownership is 8.50%.
CDI Corp. (NYSE:CDI) will report its second quarter 2014 results on Wednesday, August 6 prior to the opening of the market. CDI Corp. (NYSE:CDI) rose 7.26 percent to $15.52 Thursday on volume of 42,648.00million shares. The intra-day range of the stock was $14.61 to $15.64. CDI Corp. (NYSE:CDI) has a market capitalization of $303.18million.
Sidoti assumed coverage on shares of Alliance Fiber Optic Products Inc (NASDAQ:AFOP) in a research note issued to investors on Thursday, TheFlyOnTheWall.com reports. The firm issued a buy rating and a $28.00 price target on the stock. Alliance Fiber Optic Products Inc (NASDAQ:AFOP)’s stock on July 03, 2014 reported a increase of 7.54% to the closing price of $19.96. Its fifty two weeks range is $11.16 -$23.94. The total market capitalization recorded $367.83million. The overall volume in the last trading session was 1.12million shares. In its share capital, AFOP has 18.47million outstanding shares.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) on May 8 reported financial results for the first quarter ended March 31, 2014 and provided an update on recent corporate events. There were no revenues recognized in the first quarters of 2014 and 2013. The Company reported a net loss of $23.6 million, or $0.28 per basic and diluted share, in the first quarter of 2014, compared to a net loss of $20.7 million, or $0.30 per basic and diluted share, for the same period in 2013. On Thursday, shares of Synta Pharmaceuticals Corp. (NASDAQ:SNTA) advanced 7.91% to close the day at $4.50. Company monthly performance is recorded as 11.66%. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) quarterly revenue growth is 2.97%.
Fortuna Silver Mines Inc (NYSE:FSM) has been given an average recommendation of “Hold” by the eleven ratings firms that are presently covering the company, AnalystRatingsNetwork.com reports. Two equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and five have issued a buy recommendation on the company. Fortuna Silver Mines Inc. (NYSE:FSM) stock performance was 5.01% in last session and finished the day at $5.66. Traded volume was 195,294.00million shares in the last session and the average volume of the stock remained 201.62K shares.